Dabigatran and rivaroxaban have different risk factors for bleeding in atrial fibrillation patients

被引：0
|
作者：
Nishino, M. [1 ]
Okamoto, N. [1 ]
Tanaka, A. [1 ]
Mori, N. [1 ]
Yoshimura, T. [1 ]
Makino, N. [1 ]
Egami, Y. [1 ]
Shutta, R. [1 ]
Tanouchi, J. [1 ]
机构：
[1] Osaka Rosai Hosp, Sakai, Osaka 5918025, Japan
来源：
EUROPEAN HEART JOURNAL | 2015年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P6201
引用
收藏
页码：1080 / 1080
页数：1
相关论文
共 50 条
  • [21] Dosage of Dabigatran as a Risk Factor for Bleeding in Atrial Fibrillation
    Liu, Siyao
    Kim, Cherub O.
    Lucyk, Scott N.
    JAMA INTERNAL MEDICINE, 2015, 175 (07) : 1244 - 1245
  • [22] Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation
    Providencia, Rui
    Marijon, Eloi
    Albenque, Jean-Paul
    Combes, Stephane
    Combes, Nicolas
    Jourda, Francois
    Hireche, Hassiba
    Morais, Joao
    Boveda, Serge
    EUROPACE, 2014, 16 (08): : 1137 - 1144
  • [23] Safety of dabigatran or rivaroxaban for thoracoscopic ablation in patients with atrial fibrillation
    Im, Sung Il
    Jeong, Dong Seop
    Park, Seung-Jung
    Park, Kyoung-Min
    Huh, June
    Kim, June Soo
    On, Young Keun
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 186 : 213 - 215
  • [24] Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients
    Lai, Chao-Lun
    Chen, Ho-Min
    Liao, Min-Tsun
    Lin, Ting-Tse
    Chan, K. Arnold
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (04):
  • [25] Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan
    Miyamoto, Susumu
    Ikeda, Takanori
    Ogawa, Satoshi
    Kitazono, Takanari
    Nakagawara, Jyoji
    Minematsu, Kazuo
    Murakawa, Yuji
    Iwashiro, Sanghun
    Takeichi, Makiko
    Kidani, Yoko
    Okayama, Yutaka
    Sunaya, Toshiyuki
    Sato, Shoichiro
    Yamanaka, Satoshi
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2020, 29 (04):
  • [26] An indirect comparison of dabigatran and rivaroxaban for atrial fibrillation
    Mantha, S.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 31 (03) : 388 - 388
  • [27] Bleeding risk in patients treated with dabigatran or vitamin K antagonist for atrial fibrillation
    Darwiche, W.
    Bejan-Angoulvant, T.
    Dievart, F.
    Babuty, D.
    Angoulvant, D.
    Fauchier, L.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2017, 31 : 54 - 54
  • [28] Increased risk of thrombotic events in patients with atrial fibrillation shortly after dabigatran or rivaroxaban discontinuation
    Vene, N.
    Mavri, A.
    Gubensek, M.
    Tratar, G.
    Cuderman, T., V
    Perme, M. P.
    Blinc, A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 36 - 36
  • [29] Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation
    Jackevicius, Cynthia A.
    Tsadok, Meytal Agvil
    Essebag, Vidal
    Atzema, Clare
    Eisenberg, Mark J.
    Tu, Jack V.
    Lu, Lingyun
    Rahme, Elham
    Ho, P. Michael
    Turakhia, Mintu
    Humphries, Karin H.
    Behlouli, Hassan
    Zhou, Limei
    Pilote, Louise
    HEART, 2017, 103 (17) : 1331 - 1338
  • [30] Dabigatran but not rivaroxaban or apixaban reduces fibrinolytic resistance in patients with atrial fibrillation
    Ammollo, C. T.
    Semeraro, F.
    Incampo, F.
    Dellanoce, C.
    Paoletti, O.
    Testa, S.
    Colucci, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 118 - 118
12345